|
|
Volumn 367, Issue 3, 2012, Pages 274-275
|
|
Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AIN 457;
BRODALUMAB;
IMMUNOGLOBULIN G1;
IMMUNOGLOBULIN G4;
INTERLEUKIN 17;
INTERLEUKIN 17 RECEPTOR;
INTERLEUKIN 17RA RECEPTOR;
IXEKIZUMAB;
NEUTRALIZING ANTIBODY;
SECUKINUMAB;
UNCLASSIFIED DRUG;
MONOCLONAL ANTIBODY;
ADALIMUMAB;
BRIAKINUMAB;
ETANERCEPT;
INFLIXIMAB;
INTERLEUKIN 12;
INTERLEUKIN 23;
TUMOR NECROSIS FACTOR ALPHA;
USTEKINUMAB;
ANTIBODY PRODUCTION;
CYTOKINE NEUTRALIZATION;
DRUG ACTIVITY;
GENETIC DISORDER;
HUMAN;
IMMUNOGENICITY;
IMMUNOLOGICAL PARAMETERS;
LETTER;
MUCOCUTANEOUS CANDIDIASIS;
PRIORITY JOURNAL;
PROTEIN FAMILY;
PSORIASIS;
PSORIASIS VULGARIS;
RECEPTOR DOWN REGULATION;
SIGNAL TRANSDUCTION;
STAPHYLOCOCCUS INFECTION;
FEMALE;
IMMUNOLOGY;
MALE;
NOTE;
CARDIOVASCULAR MORTALITY;
CARDIOVASCULAR RISK;
DISEASE ASSOCIATION;
DRUG EFFICACY;
HEART DISEASE;
HEART INFARCTION;
RISK REDUCTION;
STROKE;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
FEMALE;
HUMANS;
INTERLEUKIN-17;
MALE;
PSORIASIS;
RECEPTORS, INTERLEUKIN-17;
|
|
EID: 84864008376
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1205835 Document Type: Letter |
|
Times cited : (19)
|
|
References (4)
|
